Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

RSPT vs RSPH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RSPH Wins Head-to-Head Institutional Verdict (0–0 across 6 Pillars · 3–0 Matrix Metrics)

RSPH Overall Winner 6-Pillar Tally: RSPT 0 – 0 RSPH (6 Tie) Matrix Metrics: RSPT 0 – 3 RSPH

As of Nov 20, 2026, Invesco S&P 500 Equal Weight Health Care ETF (RSPH) is the stronger overall head-to-head candidate over Invesco S&P 500 Equal Weight Technology ETF (RSPT) in the Tradestie Institutional Equity Comparison Engine, winning 3–0 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). RSPT carries a Unified Composite Score of 41.7/100 (SELL) at $53.47 (N/M Forward P/E, N/A operating margin), whereas RSPH carries 45.1/100 (HOLD) at $38.75 (N/M Forward P/E, N/A operating margin).

  • Technical & Structure Timing Caution: RSPT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.7); meanwhile RSPH trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 40.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RSPT vs RSPH
RSPT NYSE Arca
Invesco S&P 500 Equal Weight Technology ETF
Institutional Equity
$53.47
-5.96% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.66β · 41% Vol
Unified Composite Score
41.7 / 100 SELL
Tech 25.0 Fund 54.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -2.3%), weak momentum, RSI 27
RSI-14: 26.7 · SMA20: $60.56 · SMA50: $63.80
RSPH NYSE Arca Head-to-Head Winner
Invesco S&P 500 Equal Weight Health Care ETF
Institutional Equity
$38.75
-0.95% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.44β · 21% Vol
Unified Composite Score
45.1 / 100 HOLD
Tech 42.0 Fund 40.0 Flow 50.0 Mom 20.9
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 40
RSI-14: 40.4 · SMA20: $40.28 · SMA50: $38.68

6-Pillar Scorecard Institutional Category Breakdown (RSPT 0 – 0 RSPH)

Columns: Metric · RSPT · RSPH
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale Tie
Revenue Growth (YoY) N/A N/A
Earnings Growth (YoY) N/A N/A
TTM Revenue (USD) N/A N/A
Market Cap N/A N/A
3. Profitability & Quality Tie
Gross Margin N/A N/A
Operating Margin N/A N/A
Net Profit Margin N/A N/A
Return on Equity (ROE) N/A N/A
4. Balance Sheet & Cash Flow Tie
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 25.0% (7th %ile) 14.1% (<1st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RSPT (0) vs RSPH (3)
Institutional Metric RSPT RSPH Criterion Row Edge
Market Capitalization
Scale
N/A N/A Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A N/A Higher Growth Tie
Operating Margin (TTM)
Profitability
N/A N/A Higher Margin Tie
Net Profit Margin
Profitability
N/A N/A Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
N/A N/A Higher ROE Tie
52-Week Range Position
Momentum
43% ($41–$69) 74% ($30–$42) Stronger Trend RSPH
Beta / 30D Volatility
Risk Regime
1.66β · 41% Vol 0.44β · 21% Vol Lower Realized Risk RSPH
Unified Institutional Score
Composite Signal
41.7 / 100 (SELL) 45.1 / 100 (HOLD) Higher Composite RSPH
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RSPH +13.85 pp
RSPT: -16.39% · RSPH: -2.54%
3M Horizon RSPH +17.97 pp
RSPT: -15.18% · RSPH: +2.79%
6M Horizon RSPH +36.98 pp
RSPT: -12.26% · RSPH: +24.72%
1Y Horizon RSPH +2.15 pp
RSPT: +23.54% · RSPH: +25.69%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RSPT vs RSPH. Trailing 12-month operating profitability (RSPT N/A vs RSPH N/A) and valuation multiples (RSPT N/M vs RSPH N/M Forward P/E) are benchmarked directly in Pillar 4 below.

RSPT ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
RSPH ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RSPT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 25.0%
IV Percentile 7th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RSPT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RSPH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 14.1%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RSPH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RSPT Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
RSPH Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ RSPT vs RSPH Key Questions & Quantitative Answers

As of Nov 20, 2026, Invesco S&P 500 Equal Weight Health Care ETF (RSPH) is the stronger overall head-to-head candidate over Invesco S&P 500 Equal Weight Technology ETF (RSPT) in the Tradestie Institutional Equity Comparison Engine, winning 3–0 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). RSPT carries a Unified Composite Score of 41.7/100 (SELL) at $53.47 (N/M Forward P/E, N/A operating margin), whereas RSPH carries 45.1/100 (HOLD) at $38.75 (N/M Forward P/E, N/A operating margin). Technical & Structure Timing Caution: RSPT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.7); meanwhile RSPH trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 40.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

RSPT and RSPH split Growth & Scale metrics: RSPT posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with RSPH at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, RSPT generates N/A in USD-normalized revenue versus N/A for RSPH. In operating R&D and SG&A reinvestment, RSPT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RSPH.

RSPT and RSPH trade at balanced relative valuation multiples. RSPT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas RSPH trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RSPT (N/A ROE) versus RSPH (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, RSPT carries 25.0% implied volatility (7th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.66β · 41% Vol realized risk). By comparison, RSPH carries 14.1% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.44β · 21% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.